Korea Pharma한국파마
032300 · KOSDAQ · ₩032300 · 한국파마
₩8,170 ₩0 (0.00%)End-of-day · Oct 28, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩88B | ₩81B | ₩83B | ₩81B | ₩80B |
| Cost of sales | ₩56B | ₩46B | ₩46B | ₩46B | ₩44B |
| Gross profit | ₩31B | ₩35B | ₩37B | ₩35B | ₩36B |
| Operating income | −₩887M | ₩6.1B | ₩6.3B | ₩6.2B | ₩5B |
| Net income | −₩2.6B | ₩3.8B | ₩84M | −₩1.1B | ₩6.4B |
| Net income to shareholders | −₩2.6B | ₩3.8B | ₩84M | −₩1.1B | ₩6.4B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩127B | ₩112B | ₩121B | ₩131B | ₩129B |
| Current assets | ₩64B | ₩74B | ₩85B | ₩98B | ₩97B |
| Cash and equivalents | ₩28B | ₩22B | ₩41B | ₩8.4B | ₩57B |
| Total liabilities | ₩58B | ₩41B | ₩53B | ₩71B | ₩72B |
| Current liabilities | ₩57B | ₩19B | ₩33B | ₩70B | ₩25B |
| Borrowings | ₩38B | ₩23B | ₩34B | ₩53B | ₩53B |
| Total equity | ₩69B | ₩71B | ₩69B | ₩60B | ₩57B |
| Shareholders' equity | ₩69B | ₩71B | ₩69B | ₩60B | ₩57B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | ₩2.7B | ₩8B | ₩4.8B | ₩8.3B | ₩7.2B |
| Capital spending | ₩1.3B | ₩3.2B | ₩1.5B | ₩2.5B | ₩2.6B |
| Free cash flow | ₩1.4B | ₩4.8B | ₩3.3B | ₩5.8B | ₩4.6B |
| Dividends paid | ₩545M | ₩545M | ₩545M | ₩545M | ₩545M |
Consolidated where available. Amounts in won.
Also known as: Korea Pharma / 한국파마 / 032300 / KRX:032300
Source: KRX statistical information